Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Clinical Study of Camrelizumab in Combination With Anlotinib in the Treatment of Patients With Advanced Ovarian Clear Cell Carcinoma

NCT05600998 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT05600998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05600998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Clinical Study of Camrelizumab in Combination With Anlotinib in the Treatment of Patients With Advanced Ovarian Clear Cell Carcinoma
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
October 30, 2022
Completion date
February 28, 2024
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian clear cell carcinoma